- Price
- $260.10
- Day
- -2.26%
- Mkt Cap
- $34.80B
- 52W Range
- $197.81 – $495.55
- Volume
- 2.00M
- Beta
- 0.30
Find a company by name or ticker and open its page
Snapshot of fundamentals, performance, and 5D scores.
Business fundamentals and company information
Recent price action and historical returns
How the business makes money, by product and geography
Five lenses on the stock. Click any card to dive deeper.
How to read these dimensions
The five dimensions are independent lenses on a company, not a single combined score. Read them together rather than in isolation: where one dimension scores differently from the others is often the most useful place to focus your own research. Each score is built from rules and weights you can adjust, so treat them as a transparent starting point for your analysis, not a recommendation to buy or sell.
Recent news headlines and analyst price-target moves
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8, 2026, at 8:45 AM ET in Everett, Massachusetts Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, at 10:00 AM ET in New York City A live audio webcast of each pre.
4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects
ALNY, BMRN, RARE and BBIO offer rare-disease growth potential through strong products, pipeline catalysts and high unmet medical needs.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives $386.14 Consensus Target Price from Analysts
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the twenty-four research firms that are covering the company, MarketBeat.com reports. Five equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and three have issued a strong
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings
[url="]Alnylam Pharmaceuticals, Inc[/url]. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology